Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial - PubMed (original) (raw)
Clinical Trial
doi: 10.1093/annonc/mdl463. Epub 2007 Jan 17.
K Weigang-Köhler, M Fuchs, E Kettner, D Quietzsch, J Trojan, O Stötzer, S Zeuzem, F Lordick, C-H Köhne, H Kröning, T Steinmetz, H Depenbrock, V Heinemann
Affiliations
- PMID: 17229775
- DOI: 10.1093/annonc/mdl463
Free article
Clinical Trial
Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial
S Boeck et al. Ann Oncol. 2007 Apr.
Free article
Abstract
Background: A standard second-line chemotherapy regimen has yet to be defined for patients with gemcitabine (Gem)-refractory advanced pancreatic cancer (PC).
Patients and methods: In this multicenter phase II trial, patients with unresectable or metastatic PC who had progressed on single-agent Gem or a Gem-containing regimen received pemetrexed 500 mg/m(2) as a 10-min infusion every 3 weeks until disease progression or occurrence of unacceptable toxicity. The primary end point was the 3-month survival rate.
Results: A total of 192 treatment cycles were given to 52 patients. The overall response rate was 3.8% (two partial responses); 10 patients (19.2%) experienced stable disease, nine of them for >12 weeks. At least one CA 19-9 reduction > or =50% occurred in 12 patients (23.1%). The 3-month survival rate was 75% (95% confidence interval 63.2% to 86.8%), the median time to tumor progression was 7 weeks (range 1-62 weeks) and the median overall survival time was 20 weeks (range 1-84 weeks). Grade 3/4 hematological toxic effects included (percent of patients): neutropenia (17.3%), thrombocytopenia (5.8%) and anemia (3.8%). The most frequent non-hematological toxic effects were diarrhea, nausea and stomatitis/pharyngitis (23.1% each).
Conclusion: Pemetrexed is a safe treatment option with moderate activity in patients with advanced PC after failure of Gem.
Similar articles
- Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors.
Yuan Y, Cohen DJ, Love E, Yaw M, Levinson B, Nicol SJ, Hochster HS. Yuan Y, et al. Cancer Chemother Pharmacol. 2011 Aug;68(2):371-8. doi: 10.1007/s00280-010-1493-8. Epub 2010 Oct 27. Cancer Chemother Pharmacol. 2011. PMID: 20978761 Clinical Trial. - Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial.
Gridelli C, Kaukel E, Gregorc V, Migliorino MR, Müller TR, Manegold C, Favaretto A, Martoni A, Caffo O, Schmittel A, Rossi A, Russo F, Peterson P, Muñoz M, Reck M. Gridelli C, et al. J Thorac Oncol. 2007 Mar;2(3):221-9. doi: 10.1097/JTO.0b013e318031cd62. J Thorac Oncol. 2007. PMID: 17410045 Clinical Trial. - [A randomized, controlled, multicenter clinical trial comparing pemetrexed/cisplatin and gemcitabine/cisplatin as first-line treatment for advanced nonsquamous non-small cell lung cancer].
Huang Y, Liu Y, Zhou J, Xu N, Li B, Wu G, Fang J, Li K, Liu X, Liu W, Lu Y, Wang M, Liu W, Liang H, Zhang Y, Huang C, Wang S, Wang Y, Yu S, Chang J, Wang Z, Hu Z, Zhang L. Huang Y, et al. Zhongguo Fei Ai Za Zhi. 2012 Oct;15(10):576-82. doi: 10.3779/j.issn.1009-3419.2012.10.03. Zhongguo Fei Ai Za Zhi. 2012. PMID: 23075681 Free PMC article. Clinical Trial. Chinese. - Pemetrexed in pancreatic cancer.
Seitz JF, Dahan L, Ries P. Seitz JF, et al. Oncology (Williston Park). 2004 Nov;18(13 Suppl 8):43-7. Oncology (Williston Park). 2004. PMID: 15655936 Review. - Pemetrexed in pancreatic cancer.
Kindler HL. Kindler HL. Semin Oncol. 2002 Dec;29(6 Suppl 18):49-53. doi: 10.1053/sonc.2002.37472. Semin Oncol. 2002. PMID: 12571811 Review.
Cited by
- Phase II clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancer.
Chung MJ, Park JY, Bang S, Park SW, Song SY. Chung MJ, et al. Cancer Immunol Immunother. 2014 Sep;63(9):939-46. doi: 10.1007/s00262-014-1566-3. Epub 2014 Jun 12. Cancer Immunol Immunother. 2014. PMID: 24916038 Free PMC article. Clinical Trial. - Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts.
Ruess DA, Görgülü K, Wörmann SM, Algül H. Ruess DA, et al. Drugs Aging. 2017 May;34(5):331-357. doi: 10.1007/s40266-017-0453-y. Drugs Aging. 2017. PMID: 28349415 Review. - Phase II study of palliative S-1 in combination with cisplatin as second-line chemotherapy for gemcitabine-refractory pancreatic cancer patients.
Kim HJ, Yun J, Kim HJ, Kim KH, Kim SH, Lee TH, Lee SC, Bae SB, Kim CK, Lee NS, Moon JH, Park SH, Lee KT, Park SK, Won JH, Park HS, Hong DS. Kim HJ, et al. Oncol Lett. 2012 Jun;3(6):1314-1318. doi: 10.3892/ol.2012.637. Epub 2012 Mar 8. Oncol Lett. 2012. PMID: 22783441 Free PMC article. - Immunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trials.
Paniccia A, Merkow J, Edil BH, Zhu Y. Paniccia A, et al. Chin J Cancer Res. 2015 Aug;27(4):376-91. doi: 10.3978/j.issn.1000-9604.2015.05.01. Chin J Cancer Res. 2015. PMID: 26361407 Free PMC article. Review. - Systemic therapy for metastatic pancreatic adenocarcinoma.
Lawrence B, Findlay M. Lawrence B, et al. Ther Adv Med Oncol. 2010 Mar;2(2):85-106. doi: 10.1177/1758834009357188. Ther Adv Med Oncol. 2010. PMID: 21789129 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials